戻る Agenda
Session 2: Is Zynteglo representative for the ATMPs failure in Europe? Are EU systems broken for innovative therapies?
Session Chair(s)
Alexander Natz, JD
Secretary General
European Confederation of Pharmaceutical Entrepreneurs, Belgium
Topics covered in this session include:
- Case study & domino effect
- The regulatory aspects
- Historical background for withdrawals
Speaker(s)
Sophie Schmitz
P4A Partners for Access, Netherlands
Managing Partner
The Zolgensma Experience – Can one-time ATMP’s be successfully commercialized in Europe?
Oswald Bentinck
Rocket Pharmaceuticals, Inc., United States
Vice President, Global Head of Value & Access